Literature DB >> 12439111

Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization.

Jeanette Croft1, Elizabeth M Parry, Gareth J Jenkins, Shareen H Doak, John N Baxter, A Paul Griffiths, Tim H Brown, James M Parry.   

Abstract

OBJECTIVES: Barrett's oesophagus is a pre-neoplastic lesion, which develops as a complication of chronic gastro-oesophageal reflux disease and predisposes the patient to oesophageal adenocarcinoma. Our aim was to characterize karyotypic changes that may occur during the progression of Barrett's metaplasia through low-grade dysplasia and high-grade dysplasia to adenocarcinoma.
METHODS: The technique of comparative genomic hybridization was used to characterize genome-wide changes in biopsies from patients with low-grade dysplasia, low-grade dysplasia plus high-grade dysplasia, high-grade dysplasia or adenocarcinoma. Both fresh and archival material was examined.
RESULTS: Comparative genomic hybridization revealed a large amount of widespread chromosome instability at the high-grade dysplasia stage. No significant chromosome changes were detectable by comparative genomic hybridization in patients with low-grade dysplasia. Karyotypic changes in the adenocarcinoma patients were more specific than those found in the high-grade dysplasia patients. Chromosome 4 was amplified most often in high-grade dysplasia and chromosome 8q was amplified most frequently in the adenocarcinomas.
CONCLUSIONS: These data demonstrate that high-grade dysplasia is the stage exhibiting widespread chromosome instability, which is detectable by comparative genomic hybridization. This instability is undetectable in low-grade dysplasia. The chromosome variation seen at high-grade dysplasia may be the source of more specific karyotypes that progress to adenocarcinoma. Importantly, we have identified chromosome 4 amplification as being heavily involved in the initiation of Barrett's progression. Specific chromosome changes (4 and 8q) may represent important regions on which to focus attention in future studies, with a view to identifying diagnostic markers.

Entities:  

Mesh:

Year:  2002        PMID: 12439111     DOI: 10.1097/00042737-200211000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

1.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 2.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.

Authors:  Shannon M Brankley; Kenneth K Wang; Aaron R Harwood; Dylan V Miller; Mona S Legator; Lori S Lutzke; Benjamin R Kipp; Larry E Morrison; Kevin C Halling
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

4.  A relation between cell cycle and intestinal metaplasia in oesophageal biopsies using optical and digital microscopy.

Authors:  Miklós Máté; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2015-03-05       Impact factor: 3.201

5.  Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.

Authors:  William W Lockwood; Kelsie L Thu; Lin Lin; Larissa A Pikor; Raj Chari; Wan L Lam; David G Beer
Journal:  Clin Cancer Res       Date:  2012-02-10       Impact factor: 12.531

6.  Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.

Authors:  Xiaohong Li; Patricia C Galipeau; Carissa A Sanchez; Patricia L Blount; Carlo C Maley; Jessica Arnaudo; Daniel A Peiffer; Dmitry Pokholok; Kevin L Gunderson; Brian J Reid
Journal:  Cancer Prev Res (Phila)       Date:  2008-11

7.  Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Authors:  Tadayuki Akagi; Tetsuo Ito; Motohiro Kato; Zhe Jin; Yulan Cheng; Takatsugu Kan; Go Yamamoto; Alexandru Olaru; Norihiko Kawamata; Jessica Boult; Harmik J Soukiasian; Carl W Miller; Seishi Ogawa; Stephen J Meltzer; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

8.  Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Thomas G Paulson; Carlo C Maley; Xiaohong Li; Hongzhe Li; Carissa A Sanchez; Dennis L Chao; Robert D Odze; Thomas L Vaughan; Patricia L Blount; Brian J Reid
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

9.  Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome.

Authors:  J Pal; R Bertheau; L Buon; A Qazi; R B Batchu; S Bandyopadhyay; R Ali-Fehmi; D G Beer; D W Weaver; R J Shmookler Reis; R K Goyal; Q Huang; N C Munshi; M A Shammas
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

10.  Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network.

Authors:  J K R Boult; P Tanière; M T Hallissey; M J Campbell; C Tselepis
Journal:  Br J Cancer       Date:  2008-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.